MetLife Investment Management’s Mineralys Therapeutics MLYS Stock Holding History

MetLife Investment Management’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$911K	Buy	33,755 +6,929	+26%	+$190K	﹤0.01%	1575
2026 Q1	$727K	Buy	26,826 +821	+3%	+$24.1K	﹤0.01%	1567
2025 Q4	$944K	Buy	26,005 +3,296	+15%	+$132K	﹤0.01%	1464
2025 Q3	$861K	Sell	22,709 -1,305	-5%	-$28.2K	﹤0.01%	1536
2025 Q2	$325K	Buy	24,014 +7,232	+43%	+$105K	﹤0.01%	1906
2025 Q1	$266K	Sell	16,782 -342	-2%	-$3.93K	﹤0.01%	2046
2024 Q4	$211K	Hold	17,124	–	–	﹤0.01%	2281
2024 Q3	$207K	Hold	17,124	–	–	﹤0.01%	2270
2024 Q2	$200K	Buy	17,124 +5,708	+50%	+$71.9K	﹤0.01%	2245
2024 Q1	$147K	Hold	11,416	–	–	﹤0.01%	2353
2023 Q4	$98.2K	Buy	11,416 +4,353	+62%	+$34.2K	﹤0.01%	2614
2023 Q3	$67.2K	Hold	7,063	–	–	﹤0.01%	2780
2023 Q2	$120K	Hold	7,063	–	–	﹤0.01%	2573
2023 Q1	$111K	Buy	+7,063	New	+$119K	﹤0.01%	2504

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

MetLife Investment Management's MLYS Position: Q2 2026 in Review

MetLife Investment Management increased its Mineralys Therapeutics (MLYS) stake by 26% in Q2 2026, buying an estimated $190K and bringing the position to 33,755 shares worth $911K. The position accounts for ﹤0.01% of the portfolio, ranked #1575.

MetLife Investment Management first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $944K in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

MetLife Investment Management held 33,755 shares of Mineralys Therapeutics worth $911K as of Q2 2026.
MetLife Investment Management bought 6,929 Mineralys Therapeutics shares in Q2 2026, an estimated $190K.
Mineralys Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1575 holding.
MetLife Investment Management first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
MetLife Investment Management's Mineralys Therapeutics position peaked at $944K in Q4 2025.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.